Ernexa Therapeutics Inc. Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount
Ernexa Therapeutics Inc. (ERNA) reported Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount of $1.92 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance · last filed 2026-03-13
- Ernexa Therapeutics Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2025 was $1.92M, a 75.16% decline from fiscal 2024.
- Ernexa Therapeutics Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2024 was $7.72M.
- Ernexa Therapeutics Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2020 was -$939.00K.
- Ernexa Therapeutics Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2019 was -$429.00K.
| Period end | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 12 month | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $1.92M 10-K · filed 2026-03-13 | |
| 2024-12-31 | $7.72M 10-K · filed 2026-03-13 | |
| 2020-12-31 | -$939.00K 10-K · filed 2021-03-11 | |
| 2019-12-31 | -$429.00K 10-K · filed 2021-03-11 | |
| 2018-12-31 | -$20.00K 10-K · filed 2020-03-19 | |
| 2017-12-31 | $8.90M 10-K · filed 2019-03-22 | |
| 2016-12-31 | -$917.00K 10-K · filed 2018-03-09 | |
| 2015-12-31 | -$2.41M 10-K · filed 2017-03-09 | |
| 2014-12-31 | -$1.73M 10-K · filed 2016-03-15 | |
| 2013-12-31 | -$303.00K 10-K · filed 2015-03-27 | |
| 2012-12-31 | -$139.00K 10-K · filed 2014-03-31 | $139.00K 10-K · filed 2013-03-29 |
| 2011-12-31 | $1.11M 10-K · filed 2013-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |